Evidence map›Paper›PMID 32718942›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2020

Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy.

Mark E Sherman, Robert A Vierkant, Suneetha Kaggal, Tanya L Hoskin, Marlene H Frost, Lori Denison, Daniel W Visscher, Jodi M Carter, Stacey J Winham, Matthew R Jensen and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Making In Vitro Tumor Models Whole Again.Advanced healthcare materials · 2023
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Mark E ShermanDepartment of Health Sciences Research, Mayo Clinic, Jacksonville, Florida. Sherman.Mark@Mayo.edu.
Robert A VierkantMayo Clinic, Rochester, Minnesota.
Suneetha KaggalMayo Clinic, Rochester, Minnesota.
Tanya L HoskinMayo Clinic, Rochester, Minnesota.
Marlene H FrostDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Lori DenisonDepartment of Information Technology, Mayo Clinic, Rochester, Minnesota.
Daniel W VisscherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Jodi M CarterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Stacey J WinhamMayo Clinic, Rochester, Minnesota.
Matthew R JensenMayo Clinic, Rochester, Minnesota.
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
Celine M VachonDivision of Epidemiology, Mayo Clinic, Rochester, Minnesota.
Amy C DegnimDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · US

Funding

Predicting Breast Cancer Risk after Benign Percutaneous BiopsyR01CA229811 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, SHERMAN, MARK E · 2018 to 2022
$3.5M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA229811NCI NIH HHS R01 CA237602
6 · The paper itself

Abstract

Over one million women in the United States receive biopsy diagnoses of benign breast disease (BBD) each year, which confer a 1.5-4.0-fold increase in breast cancer risk. Studies in the general population suggest that nonsteroidal anti-inflammatory agents (NSAID) lower breast cancer risk; however, associations among women with BBD are unknown. We assessed whether NSAID use among women diagnosed with BBD is associated with lower breast cancer risk. Participants included 3,080 women (mean age = 50.3 ± 13.5 years) in the Mayo BBD surgical biopsy cohort diagnosed between January 1, 1992 and December 31, 2001 who completed breast cancer risk factor questionnaires that assessed NSAID use, and whose biopsies underwent detailed pathology review, masked to outcome. Women were followed from date of BBD biopsy to breast cancer diagnosis (main outcome) or censoring (death, prophylactic mastectomy, reduction mammoplasty, lobular carcinoma

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalBiopsyBreastBreast NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedPrognosisRisk AssessmentYoung AdultAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID32718942
PMCPMC9509660
OpenAlexW3044154034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.